– USA, CO – EvoEndo, Inc., a medical device company developing platforms for Unsedated Transnasal Endoscopy, today announced the appointment of David Pierce to its Board of Directors, bringing a wealth of experience and wisdom from his 30-year track record of success at Boston Scientific and his current activity as an Independent Trustee with Diversified Healthcare Trust.
“We are extremely pleased to have the opportunity to work with Dave Pierce. Dave understands how to successfully penetrate and grow new markets with novel technologies aimed at providing patients and physicians with exceptional clinical outcomes,” said CEO Jonathan Hartmann.
About David Pierce
David Pierce has a deep level of knowledge in the field of endoscopy and understands what it takes to drive long-term profitable growth.
During his long tenure at Boston Scientific, Mr. Pierce’s roles included EVP and President of MedSurg, President of Endoscopy, SVP and President of the Urology Division, and SVP and President of the Endoscopy Division.
Mr. Pierce is a trustee of Norwich University and previously served as a director of the Medical Device Manufacturers Association and MassMedic. He was the strategic advisory board chair of the American Gastroenterology Association Center for GI Innovation and a director of the American Society of Gastrointestinal Endoscopy Foundation. Mr. Pierce attained the rank of Captain in the United States Army.
About EvoEndo
EvoEndo, Inc. is a medical device company developing sterile single-use, flexible endoscopes that enable unsedated endoscopic procedures. EvoEndo’s technology allows pediatric patients and adults to consider an unsedated option for routine endoscopies in a clinic setting without general anesthesia or sedation.
For more information: https://www.evoendo.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
